3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Phase 1
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Lymphoid
1
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Colonic Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Cyclophosphamide
171
Docetaxel
164
Paclitaxel
160
Trastuzumab
152
Capecitabine
130
Tamoxifen
119
Letrozole
105
Epirubicin
93
Doxorubicin
83
Anastrozole
83
exemestane
77
Fulvestrant
75
Carboplatin
64
Fluorouracil
63
Radiotherapy
61
pertuzumab
59
Gemcitabine
55
Vinorelbine
43
Goserelin
39
eribulin
36
130-nm albumin-bound paclitaxel
36
palbociclib
32
Bevacizumab
32
ribociclib
30
Zoledronic Acid
29
Lapatinib
29
Methotrexate
28
Drug Therapy
28
Chemotherapy, Adjuvant
28
Ado-Trastuzumab Emtansine
24
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Doxycycline
×
Breast
×
Clear all
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn